[Skip to Content]
[Skip to Content Landing]
Views 209
Citations 0
Comment & Response
October 2018

Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer

Author Affiliations
  • 1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland
JAMA Oncol. 2018;4(10):1435-1436. doi:10.1001/jamaoncol.2018.3261

To the Editor In their analysis for limited-stage small cell lung cancer, Pezzi et al1 report that substantial numbers of patients are not receiving standard-of-care treatment. Notably, Medicare/Medicaid beneficiaries were less likely to receive radiotherapy vs the privately insured. The authors theorize that similar effects by insurance status were not observed for chemotherapy partially due to competitive chemotherapy reimbursement afforded by the 340b Drug Pricing Program.

×